In vitro Antifungal Susceptibility Testing of Clinically-isolated Trichophyton Species to Luliconazole

[1]  K. Makimura,et al.  In vitro antifungal activities of luliconazole, a new topical imidazole. , 2009, Medical mycology.

[2]  M. Lavrador,et al.  Dermatophyte susceptibilities to antifungal azole agents tested in vitro by broth macro and microdilution methods. , 2008, Revista do Instituto de Medicina Tropical de Sao Paulo.

[3]  Daniel de Assis Santos,et al.  Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). , 2007, Journal of medical microbiology.

[4]  H. Yamaguchi,et al.  In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  J. S. Hamdan,et al.  Determination of susceptibility/resistance to antifungal drugs of Trichophyton mentagrophytes isolates by a macrodilution method. , 2005, Canadian journal of microbiology.

[6]  H. Yamaguchi,et al.  In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[7]  H. Yamaguchi,et al.  In vitro activity of novel imidazole antifungal agent NND-502 against Malassezia species. , 2003, International journal of antimicrobial agents.

[8]  J. Shin.  Current Status of Antifungal Suscepitibility Testing: Technical Advances and Clinical Applications. , 2002 .

[9]  A. Rubin,et al.  Six Novel Antimycotics , 2002, American journal of clinical dermatology.

[10]  Aditya K. Gupta,et al.  Ciclopirox: an overview , 2001, International journal of dermatology.

[11]  Ryder Ns.  Activity of terbinafine against serious fungal pathogens. , 1999 .

[12]  H. Yamaguchi,et al.  Inhibition of sterol 14 alpha-demethylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent. , 1999, Medical Mycology.

[13]  M. Yoshida,et al.  Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections. , 1999, International journal of antimicrobial agents.

[14]  B. Piraccini,et al.  Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.

[15]  H. Yamaguchi,et al.  In Vitro and In Vivo Antidermatophyte Activities of NND-502, a Novel Optically Active Imidazole Antimycotic Agent , 1998, Antimicrobial Agents and Chemotherapy.

[16]  E. Evans.  A comparison of terbinafine (Lamisil®) 1% cream given for one week with clotrimazole (Canesten®) 1% cream given for four weeks, in the treatment of tinea pedis , 1994, The British journal of dermatology.

[17]  M. Stiller,et al.  TREATMENT OE DERMATOPHYTOSES II: NEWER TOPICAL ANTIEUNGAL DRUGS , 1993 .

[18]  N. Ryder,et al.  Terbinafine: Mode of action and properties of the squalene epoxidase inhibition , 1992, The British journal of dermatology.

[19]  A. Espinel-Ingroff,et al.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests , 1991, Journal of clinical microbiology.

[20]  G. Petrányi,et al.  Antifungal activity of the allylamine derivative terbinafine in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[21]  D. Feingold,et al.  Mechanisms of action of the antimycotic imidazoles. , 1981, The Journal of investigative dermatology.